The shareholders have been sold short..
Why did'nt Viralytics wait to release the clinical data from the keynote trail before
doing an agreement with merck.
I expect the data to be released to be outstanding and that would have given viralytics a much
better bargaining position.
whereby cavatek will have multiple uses in combination.A very attractive proposition to big pharma
with pd1 inhibitors.
The acquisition agreement will be finalised by the end of june.The keynote trail data is to released
2q2018 so the shareholders will have prior knowledge before deciding which way to vote.
Is it possible now that viralytics will delay releasing the keynote trial data until after the deadline for the acquistion.
If big pharma get access to outstanding keynote trial data before the vote then maybe a bid from another party.
VLA Price at posting:
$1.70 Sentiment: Hold Disclosure: Held
